Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China’s Largest Vaccine Production Base Sets Up In Henan Province

This article was originally published in PharmAsia News

Executive Summary

China's National Engineering Research Center for Viral Bio-Technology has set up its Henan branch at Henan University. At the same time, the center, Henan University and Shangcheng county jointly established the Henan biology valley in Xinyang city, Henan province. With a Phase I investment of RMB 200 million out of a total of RMB 500 million, the biology valley will house China's largest vaccine production base and biopharmaceutical industrialization facility under the National 863 Program. The project plans to realize a production value of RMB five billion in five years and RMB 10 billion in 10 years. The Henan branch will initially develop programs for novel vaccines for influenza, epidemic hemorrhagic fever and cervical cancer. (Click here for more - Chinese language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067578

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel